Skip Navigation


Annals of Oncology Advance Access originally published online on August 28, 2006
Annals of Oncology 2006 17(10):1539-1545; doi:10.1093/annonc/mdl162
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/10/1539    most recent
mdl162v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Giné, E
Right arrow Articles by López-Guillermo, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giné, E
Right arrow Articles by López-Guillermo, A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

hematologic malignancies

The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma

E Giné, S Montoto, F Bosch, L Arenillas, S Mercadal, N Villamor, A Martínez, L Colomo, E Campo, E Montserrat and A López-Guillermo*

Institute of Hematology and Oncology, Department of Hematology and Hematopathology Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain

*Correspondence to: Dr A. López-Guillermo, Department of Hematology, Hospital Clínic Villarroel n° 170, 08036-Barcelona, Spain. Tel: +34-93-2275475. Fax: +34-93-2275484. E-mail: alopezg{at}clinic.ub.es

Background: Histological transformation (HT) is a well-known event in patients with follicular lymphoma (FL) conferring an unfavorable prognosis. The aim of the study was to analyze incidence and risk factors for HT in a large series of FL patients.

Patients and methods: 276 patients (median age: 54 years; M139/F137) diagnosed with FL (42% grade 1, 51% 2, 7% 3) in a single institution were studied. Initial treatment consisted of combined chemotherapy in most cases. Median survival was 11.3 years. Main clinic and biological variables were assessed for HT and survival.

Results: 30 of 276 patients (11%) presented HT after a median follow-up of 6.5 years, with a risk of 15% and 22% at 10 and at 15 years, respectively. All HT corresponded to diffuse large B-cell lymphoma (DLBCL). Grade 3 histology, nodal areas >4, increased LDH and ß2-microglobulin, and high-risk IPI and FLIPI were associated with HT. In multivariate analysis, grade 3 histology and FLIPI retained prognostic significance. Only FLIPI predicted HT in grade 1–2 patients. 28 patients received salvage treatment for HT, with a CR rate of 52%. Median survival from transformation was 1.2 years, with 6/13 CR patients being alive >5 years after HT.

Conclusion: FLIPI and histology were the most important variables predicting HT. Upon HT, only patients achieving CR reached prolonged survival, thus emphasizing the need for effective therapies once this event occurs.

Key words: follicular lymphoma, transformation, FLIPI


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. Noy, H. Schoder, M. Gonen, M. Weissler, K. Ertelt, C. Cohler, C. Portlock, P. Hamlin, and H. W. D. Yeung
The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)
Ann. Onc., March 1, 2009; 20(3): 508 - 512.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. Al-Tourah, K. K. Gill, M. Chhanabhai, P. J. Hoskins, R. J. Klasa, K. J. Savage, L. H. Sehn, T. N. Shenkier, R. D. Gascoyne, and J. M. Connors
Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma
J. Clin. Oncol., November 10, 2008; 26(32): 5165 - 5169.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M. Federico, C. Guglielmi, S. Luminari, C. Mammi, L. Marcheselli, U. Gianelli, A. Maiorana, F. Merli, M. Bellei, S. Pozzi, et al.
Prognostic relevance of serum {beta}2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study
Haematologica, November 1, 2007; 92(11): 1482 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Klapper, E. Hoster, L. Rolver, C. Schrader, D. Janssen, M. Tiemann, H.-W. Bernd, O. Determann, M.-L. Hansmann, P. Moller, et al.
Tumor Sclerosis but Not Cell Proliferation or Malignancy Grade Is a Prognostic Marker in Advanced-Stage Follicular Lymphoma: The German Low Grade Lymphoma Study Group
J. Clin. Oncol., August 1, 2007; 25(22): 3330 - 3336.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Montoto, A. J. Davies, J. Matthews, M. Calaminici, A. J. Norton, J. Amess, S. Vinnicombe, R. Waters, A. Z.S. Rohatiner, and T. A. Lister
Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
J. Clin. Oncol., June 10, 2007; 25(17): 2426 - 2433.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.